Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-09-28
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ibrutinib and palbociclib in
treating patients with previously treated mantle cell lymphoma. Ibrutinib and palbociclib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Palbociclib may also help ibrutinib work better by making cancer cells more sensitive to the
drug.